CD22 and acute lymphoblastic leukemia: Consolidation with HSCT was shown to be favorably associated with better EFS (p = 0.016) also in a phase I trial evaluating a CD22-targeted/4-1BB CAR T-cell in CAYA with B-ALL [146].